|
Procter & Gamble
Procter & Gamble Pharmaceuticals, Inc. (P&GP), a division of The Procter & Gamble Company (NYSE: PG), has successfully developed and marketed a wide range of prescription products since the 1980s, including Actonel ®, Asacol ®, Dantrium ®, Didronel ®, and Macrobid ®. P&GP is a unique pharmaceutical company with deep experience and proven capabilities in our focus areas. P&GP employs a Connect & Develop model for new product development and in-licenses or acquires 100 percent of its new drug candidates from biotech and pharmaceutical industry relationships. P&GP is committed to leveraging this model to build brands to address unmet needs in the areas of gastrointestinal, musculoskeletal and women's health. The P&GP community consists of more than 3,000 employees working in over 22 countries worldwide. For more information on P&GP and its prescription product portfolio, please visit www.pgpharma.com . As one of Procter & Gamble's diverse healthcare businesses, P&GP benefits from the consumer understanding of the world's largest marketing company. Three billion times a day, P&G brands touch the lives of people around the world. P&G has one of the strongest portfolios of quality, leadership brands in consumer health and wellness, including Align ®, Always ®, Crest ®, Metamucil ®, Oral-B ®, Pepto-Bismol ®, Prilosec OTC ®, Scope ®, Tampax ® and Vicks ®, in addition to its trusted consumer brands, including Ariel ®, Braun ®, Bounty ®, Charmin ®, Dawn ®, Downy ®, Duracell ®, Folgers ®, Gillette ®, Head & Shoulders ®, Iams ®, Lenor ®, Mach3 ®, Olay ®, Pantene ®, Pampers ®, Pringles ®, Tide ®, Wella ® and Whisper ® . The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.
Asacol is a delayed-release oral mesalamine tablet indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses). Asacol is a non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs). Asacol was well-tolerated in clinical studies. Overall, the incidence of adverse events with Asacol was comparable to placebo. In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35% vs. 36%), abdominal pain (18% vs. 14%), eructation (16% vs. 15%), pain (14% vs. 8%) and nausea (13% vs. 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs. 50%), rhinitis (42% vs. 36%), diarrhea (35% vs. 50%), abdominal pain (32% vs. 44%) and flatulence (24% vs. 30%). Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol. Please visit www.Asacol.com/pdf/us-asacol.pdf for full prescribing information. Additional information about Asacol can be found by visiting www.Asacol.com.
|
